The Journal of Rheumatology · Nov 15, 2026

Association between NT-proBNP levels and future cardiovascular events in systemic lupus erythematosus: a multicenter longitudinal cohort study

By Mageau A, Belhadi D, Boutten A et al.

Objective: Current strategies for identifying individuals at high risk of cardiovascular events (CVE) in systemic lupus erythematosus (SLE) are lacking. A previous cross-sectional study in SLE showed that NT-proBNP > 133 pg/mL was associated with cardiovascular damage. Our objective was to assess the association between NT-proBNP at a threshold of 133 and incident CVE in SLE. Methods: All SLE patients who were included in the randomised controlled trial PLUS between 2007 and 2010 in France were screened. Patients with a history of CVE, an unavailable serum sample at PLUS inclusion, or incomplete follow-up were excluded from the primary analysis. The primary endpoint was the occurrence of CVE during follow-up. Results: A total of 351 patients (out of 573 included in PLUS) were analyzed. Of these patients, 316 (90.0%) were women with a median age of 38 [30-48] years. Among them, 24 (6.8%) patients experienced at least one CVE that occurred a median of 5 [3-7] years after baseline. Five patients had more than one CVE. In the multivariable analysis, age, dyslipidemia and NT-proBNP were significantly associated with the occurrence of CVE. NT-proBNP was >133pg/mL in 22 (6.3%) patients at baseline. The 133 pg/ml threshold was significantly associated with the occurrence of CVE during follow-up (adjusted hazard ratio [CI 95]: 2.94; 95% CI: 1.12–7.71). Conclusion: A NT-proBNP threshold of 133 pg/ml is associated with future CVE in SLE. SLE care guidelines could consider including NT-proBNP measurement in order to better stratify the cardiovascular prevention strategies in this high-risk population.

doi.org/10.3899/jrheum.2026-0671PubMed 43035238Biomarkers

AgingResearch.News